Advertisement
Advertisement
KRYS
Krystal Biotech, Inc. Common Stock
345.82
USDSponsored
+0.86
+0.25%
Sep 25, 15:59 UTC -4
Closed
After-Market
351.76
+5.94
+1.72%
KRYS Earnings Reports
Positive Surprise Ratio
KRYS beat 21 of 36 last estimates.
58%
Next Report
Date of Next Report
Nov 02, 2026
Estimate for Q3 26 (Revenue/ EPS)
$132.74M
/$1.88
Implied change from Q2 26 (Revenue/ EPS)
+11.34%
/+5.03%
Implied change from Q3 25 (Revenue/ EPS)
+35.73%
/-29.32%
Krystal Biotech, Inc. Common Stock earnings per share and revenue
On Aug 03, 2026, KRYS reported earnings of 1.79 USD per share (EPS) for Q2 26, beating the estimate of 1.68 USD, resulting in a 6.00% surprise. Revenue reached 119.22 million, compared to an expected 123.48 million, with a -3.45% difference. The market reacted with a -8.37% price change (close before vs. close after earnings).
Looking ahead to Q3 26, 6 analysts forecast an EPS of 1.88 USD, with revenue projected to reach 132.74 million USD, implying an increase of 5.03% EPS, and increase of 11.34% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Abivax SA - ADR
Report Date
Sep 21, 2026 For Q2 26
Estimate
-$1.82
Actual
-$2.09
Surprise
-14.47%
AnaptysBio, Inc. Common Stock
Report Date
Sep 21, 2026 For Q2 26
Estimate
$0.00
Actual
$5.11
Surprise
>+10,000.00%
BlossomHill Therapeutics, Inc. Common Stock
Report Date
Sep 18, 2026 For Q2 26
Estimate
-$1.03
Actual
-$8.75
Surprise
-746.56%
Vogenx Inc Common Stock
Report Date
Sep 17, 2026 For Q2 26
Estimate
-$0.07
Actual
-$0.07
Surprise
+1.96%
Benitec Biopharma Inc. Common Stock
Report Date
Sep 14, 2026 For Q4 26
Estimate
-$0.27
Actual
-$0.26
Surprise
+5.59%
AYTU BioPharma, Inc. Common Stock
Report Date
Sep 22, 2026 For Q4 26
Estimate
-$0.33
Actual
-$0.05
Surprise
+84.92%
Neuphoria Therapeutics Inc. Common Stock
Report Date
Sep 18, 2026 For Q4 26
Estimate
-$0.57
Actual
-$0.95
Surprise
-66.32%
NewcelX Ltd. Ordinary Shares
Report Date
Sep 18, 2026 For Q2 26
Estimate
-$0.54
Actual
-$0.96
Surprise
-77.58%
FAQ
What were Krystal Biotech, Inc. Common Stock's earnings and revenue for the latest quarter Q2 2026?
For Q2 2026, Krystal Biotech, Inc. Common Stock reported EPS of $1.79, beating estimates by 6%, and revenue of $119.22M, -3.45% below expectations.
How did the market react to Krystal Biotech, Inc. Common Stock's Q2 2026 earnings?
The stock price moved down -8.37%, changed from $341.12 before the earnings release to $312.57 the day after.
When is Krystal Biotech, Inc. Common Stock expected to report next?
The next earning report is scheduled for Nov 02, 2026.
What are the forecasts for Krystal Biotech, Inc. Common Stock's next earnings report?
Based on 6
analysts, Krystal Biotech, Inc. Common Stock is expected to report EPS of $1.88 and revenue of $132.74M for Q3 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.